Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Actavis plc has entered into an agreement with Pfizer, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Celebrex® (celecoxib) 50-mg, 100-mg, 200-mg and 400-mg capsules. Celebrex® is indicated for the...

FDA has approved Sylvant (siltuximab) to treat patients with multicentric Castleman's disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes). Sylvant is marketed by Janssen Biotech Inc., based in Horsham,...

Eli Lilly and Company has received FDA approval for CYRAMZAâ„¢ (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after...

The specialty pharmaceutical company Valeant Pharmaceuticals International Inc. has made an approximate $45.7 billion unsolicited bid for specialty pharmaceutical company Allergan, Inc.. Allergan has acknowledged the bid, but says it plans to take...

Glenmark Generics has issued a Class II voluntary recall of 2904 bottles of rantidine Tablets USP, 150 mg, 500-count bottles, prescription only, due to a pharmacist complaint of a "foreign material,"  identified as a metoprolol tartrate...

Mylan Inc. reports that its US-based subsidiary Mylan Pharmaceuticals Inc. has launched Xulane™ (norelgestromin/ethinyl estradiol transdermal system 150/35 mcg per day), the generic version of Janssen Pharmaceuticals Inc.'s Ortho Evra®...